Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.80 USD
+0.87 (1.26%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $69.80 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Zacks News
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PRFZ
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
If You Invested $1000 in Exact Sciences a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PRFZ
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Zacks.com featured highlights ColgatePalmolive, BigCommerce and Exact Sciences
by Zacks Equity Research
ColgatePalmolive, BigCommerce and Exact Sciences have been highlighted in this Screen of The Week article.
3 Top Earnings Acceleration Stocks Worth Buying
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are ColgatePalmolive (CL), BigCommerce (BIGC) & Exact Sciences (EXAS).
Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
Miromatrix Medical Inc. (MIRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Miromatrix Medical Inc. (MIRO) delivered earnings and revenue surprises of 10.81% and 9,200%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session.
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Down 6.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent Biosolutions (EBS) Down 28.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $66.28 in the latest trading session, marking a +1.33% move from the prior day.
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed the most recent trading day at $65.41, moving +1.93% from the previous trading session.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Exact Sciences (EXAS) Stock Moves -0.16%: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $64.36, marking a -0.16% move from the previous day.
Exact Sciences (EXAS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $64.46, marking a +1.45% move from the previous day.
Exact Sciences (EXAS) Stock Moves -1.42%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $66.08 in the latest trading session, marking a -1.42% move from the prior day.
Exact Sciences (EXAS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $62.45, marking a +0.19% move from the previous day.